US6270790B1 - Soft, convex shaped chewable tablets having reduced friability - Google Patents

Soft, convex shaped chewable tablets having reduced friability Download PDF

Info

Publication number
US6270790B1
US6270790B1 US09/135,723 US13572398A US6270790B1 US 6270790 B1 US6270790 B1 US 6270790B1 US 13572398 A US13572398 A US 13572398A US 6270790 B1 US6270790 B1 US 6270790B1
Authority
US
United States
Prior art keywords
tablet
active ingredient
coated
tablets
weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US09/135,723
Inventor
Ronni L. Robinson
James R. Damon
James R. Mossop
Michael D. Palmer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kenvue Brands LLC
Original Assignee
McNeil PPC Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by McNeil PPC Inc filed Critical McNeil PPC Inc
Priority to US09/135,723 priority Critical patent/US6270790B1/en
Assigned to MCNEIL-PPC, INC. reassignment MCNEIL-PPC, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: DAMON, JAMES R., MOSSOP, JAMES R., PALMER, MICHAEL D., ROBINSON, RONNI
Priority to PT99306455T priority patent/PT997143E/en
Priority to AT99306455T priority patent/ATE381320T1/en
Priority to KR1019990033896A priority patent/KR20000017352A/en
Priority to DE69937780T priority patent/DE69937780T2/en
Priority to EP99306455A priority patent/EP0997143B1/en
Priority to CA002280628A priority patent/CA2280628C/en
Priority to ZA9905248A priority patent/ZA995248B/en
Priority to ES99306455T priority patent/ES2299234T3/en
Priority to CN99119112A priority patent/CN1249176A/en
Priority to BR9903736-0A priority patent/BR9903736A/en
Priority to AU44565/99A priority patent/AU773549B2/en
Priority to ARP990104128A priority patent/AR022065A1/en
Priority to NZ337310A priority patent/NZ337310A/en
Priority to JP11232034A priority patent/JP2000095673A/en
Priority to CO99052293A priority patent/CO5130019A1/en
Priority to SA99200655A priority patent/SA99200655B1/en
Priority to US09/880,179 priority patent/US6471991B2/en
Publication of US6270790B1 publication Critical patent/US6270790B1/en
Application granted granted Critical
Priority to US10/226,540 priority patent/US7029699B2/en
Assigned to JOHNSON & JOHNSON CONSUMER INC. reassignment JOHNSON & JOHNSON CONSUMER INC. MERGER AND CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: JOHNSON & JOHNSON CONSUMER INC., MCNEIL-PPC, INC.
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals

Definitions

  • the present invention relates to soft, convex-shaped compressed chewable tablets and a process for preparing such tablets.
  • Chewable tablets are widely used in the pharmaceutical industry for patients, such as children, who have who have difficulty swallowing conventional tablets or capsules.
  • Children's TYLENOL® Chewable Tables are an example of a pediatric chewable acetaminophen tablet sold in the United States. These tables are packaged in bottles and have a flat face, beveled edge shape. Samples of these tablets obtained from retail locations had hardnesses (average of ten tablets) ranging from 5.3-13.1 kp or normalized hardnesses of 12.3-30.5 kp/cm 2 .
  • Rapidly disintegrating dosage forms such as those described in U.S. Pat. No. 5,464,632, issued Nov. 7, 1995, are also available for patients, particularly aged and pediatric patients, having difficluties swallowing tablets and caplets.
  • rapidly disintegrating dosage forms currently available are highly friable, and require the use of special handling and costly packaging, e.g., specially designed blister packs, to prevent breakage or chipping of the tablets.
  • Tablet shape also affects tablet friability.
  • T. Chakrabarti et al. in The Indian Journal of Pharmacy, Vol. 38, No. 3, pp. 62-65 (1975) disclose that lower friability was observed in beveled flat tablets followed by standard convex and plain flat tablets. Similarily, K. Sugimori et al. in Powder Technology , Vol. 58, pp. 259-264 (1989) report that capping occurs more often in convex-shaped tablets than flat faced tablets.
  • the present invention provides a compressed, chewable tablet containing at least one active ingredient, a water-disintegratable, compressible carbohydrate and a binder. These components are dry blended and compressed into a convex-shaped tablet having a hardness of about 2 to about 11 kp/cm 2 .
  • the tablet has a friability of less than 1%.
  • the compressed, chewable tablet is prepared by dry blending the active ingredient, water-disintegratable, compressible carbohydrate and binder, and then compressing into a convex-shaped tablet having a hardness of about 2 to about 11 kp/cm 2 . If the active ingredient has an objectionable taste, it is coated with a taste masking composition.
  • the convex tablet geometry significantly reduces tablet friability at a given compression force. This reduction in tablet friability allows for the use of lower compression forces and lower tablet hardness, while maintaining the ability to process the tablets with conventional bulk handling equipment and package them in conventional bottles.
  • FIGS. 1 a and 1 b are front and side views, respectively, of a bi-convex tablet of the present invention.
  • FIG. 2 is a graph of friability (wt % loss) vs. hardness (kp/cm 2 ) for a flat face, beveled edge tablet (control) and a concave tablet of the present invention.
  • the compressed, chewable tablets of the present invention comprise at least one active ingredient, a water-disintegratable, compressible carbohydrate, and a binder. These ingredients are dry blended and then compressed into a convex-shaped tablet having a hardness of about 2 to about 11, preferably about 5 to about 8.5, kp/cm 2 . Tablet friability is also preferably less than 1%.
  • Tableting machines preferably those capable of applying separate pre-compression and main compression forces, are used to compress the ingredients into tablets. Since the ingredients are dry blended, water-soluble, as well as water-insoluble, active ingredients can be used in the tablet. If the active ingredients have an objectionable taste they may be coated with a taste masking composition.
  • the water-disintegratable, compressible carbohydrate used in the present invention includes carbohydrate materials conventionally used in tablets.
  • the carbohydrates facilitate the breakup of the dosage form after oral administration, and are described in Lieberman et al., Pharmaceutical Dosage Forms , Marcel Dekker, Inc., New York, 2 Ed. Vol. 1, pp. 205-209 (1990), which is hereby incorporated by reference.
  • Preferred water-disintegratable, compressible carbohydrates include mannitol, sorbitol, maltitol, dextrose, sucrose, xylitol, lactose, and mixtures thereof.
  • the binder in the present invention is used to add cohesiveness to the formulation, thereby providing the necessary bonding to form a cohesive mass or compact upon compression.
  • These binders are conventionally used in direct compression tablets and are described in Lieberman et al., Pharmaceutical Dosage Forms, 2 Ed., Vol. 1, pp. 209-214 (1990), which is hereby incorporated by reference.
  • Preferred binders include cellulose, cellulosic derivatives, polyvinyl pyrrolidone, starch, modified starch, and mixtures thereof, and, in particular, microcrystalline cellulose available from FMC Corp. under the trademark AVICEL® PH 101.
  • the tablets of the present invention are used to orally administer a wide variety of active ingredients.
  • Suitable active ingredients include pharmaceuticals, minerals, vitamins and other nutraceuticals.
  • Suitable pharmacuticals include analgesics, decongestants, expectorants, antitussives, antihistamines, gastrointestinal agents, diuretics, bronchodilators, sleep-inducing agents and mixtures thereof.
  • Preferred pharmaceuticals include acetaminophen, ibuprofen, flurbiprofen, naproxen, aspirin, pseudoephedrine, phenylpropanolamine, chlorpheniramine maleate, dextromethorphan, diphenhydramine, famotidine, loperamide, ranitidine, cimetidine, astemizole, terfenadine, terfenadine carboxylate, cetirizine, mixtures thereof and pharmaceutically acceptable salts thereof.
  • the active ingredients are present in the tablet in a therapeutic effective amount, which is an amount that produces the desired therapeutic response upon oral administration and can be readily determined by one skilled in the art. In determining such amounts, the particular compound being administered, the bioavailability characteristics of the ingredient, the dose regime, the age and weight of the patient, and other factors must be considered.
  • a coated particle containing the active ingredient coated with a taste masking coating is employed.
  • the active may be coated with taste masking coatings known in the art, such as those described in U.S. Pat. No. 4,851,226, issued Jul. 25, 1989, to T. W. Julian, et al.; U.S. Pat. No. 5,075,114, issued Dec. 24, 1991 to E. J. Roche; and U.S. Pat. No. 5,489,436, issued Feb. 6, 1996, all of which are hereby incorporated by reference.
  • Commercially available taste masked active ingredients may also be employed.
  • acetaminophen particles which are encapsulated with ethylcellulose or other polymers by a coaccervation process may be used in the present invention.
  • Coaccervation-encapsulated acetaminophen may be purchased commercially from Eurand America, Inc. Vandalia, Ohio, or from Circa Inc., Dayton, Ohio.
  • coated particle refers to a solid active ingredient in the form of a crystal or particle, an agglomerate of individual particles, or a granuled particle, which has been encapsulated with a the taste masking composition, either by film coating or by another process such as coaccervation.
  • the tablet may provide for immediate or sustained release of the active.
  • Taste masking compositions suitable for use as coatings are provided in the following table:
  • PVP polyvinylpyrrolidone
  • HPC Hydroxypropyl cellulose
  • HEC Hydroxyethyl cellulose
  • HPMC Hydroxypropylmethyl cellulose
  • CA Cellulose Acetate
  • CAB Cellulose Acetate
  • 2-VPS 2-Vinyl pyridine styrene EUDRAGIT TM E-100 — methylaminoethyl-methacrylate and neutral methacrylic acid esters available from Rohm Pharma GmbH, Germany.
  • Substantially all of the active ingredient or granulated active ingredient should be coated with a layer of a taste masking composition having a thickness of about 3 to about 10 microns.
  • the coating should be substantially free of cracks, holes or other imperfections when examined under a scanning electron microscope at 100-500 ⁇ .
  • the active ingredient is preferably coated with a blend of a first polymer selected from the group consisting of cellulose acetate and cellulose acetate butyrate and a second polymer selected from the group consisting of polyvinyl pyrrolidone and hydroxypropyl cellulose.
  • the weight ratio of the first polymer to the second polymer in this blend is within the range of about 90:10 to about 50:50 and preferably about 90:10 to about 70:30.
  • the blend of first and second polymers may be coated directly onto the pure active ingredient or may be coated onto a granulated particle containing the active.
  • a granulated particle such as a rotogranulated particle
  • the active will constitute from about 5 to about 90 weight percent of the particle, with the remainder being the binder or filler.
  • Suitable binders for the granulated particles include polyvinyl pyrrolidone, hydroxypropylmethyl cellulose, hydroxypropyl cellulose, and other pharmaceutically acceptable polymers.
  • Fillers suitable for use in such granulated particles include lactose, confectioner's sugar, mannitol, dextrose, fructose, other pharmaceutically acceptable saccharides and microcrystalline cellulose.
  • the coated particles may be prepared by spraying an organic solvent solution of the polymeric blend onto the active ingredient, or a granulated particle containing the active ingredient, in a fluidized bed, such as a Wurster coater or a rotogranulator.
  • organic solvents may be used to prepare the solution of the polymeric blend.
  • a preferred solvent is a mixture of acetone and methanol, but other solvent systems may be employed, including methylene chloride, methylene chloride-methanol, acetone-ethyl acetate, toluene-ethanol and acetone-ethanol.
  • the proportion of the polymer blend in the solvent solution will be within the range of about 5 to about 20, preferably about 8 to about 15, weight percent, depending on the solvent and other similar considerations.
  • air which may be heated, passes through a bed of the active ingredient solids to fluidize them, and the solution of the polymeric blend is sprayed onto the fluidized bed and thereby coats the active.
  • the air passing through the bed dried the coating onto the active ingredient, so that a dry coated granule is obtained.
  • Conventional fluidized bed coating equipment may be used in the present invention to coat the active ingredient or the rotogranulated particle containing the pharmaceutical.
  • This equipment includes Wurster fluid-bed coaters, where the solution of the polymer blend is sprayed from the bottom of the chamber, and a rotogranulator, where the solution of the polymer blend is tangentially sprayed.
  • the coated particle in a dried state, generally contains about 5 to about 60, preferably about 10 to 40, weight percent of the blend of the first and second polymers.
  • the exact proportions of the coating to the active ingredient can, however, vary depending upon the level of taste masking required and whether a sustained or immediate release of the active is desired. Larger proportions of the coating tend to provide a sustained release effect and enhance taste masking.
  • the tablet may also contain ingredients other than the coated particles, carbohydrate and binder.
  • the additional ingredients include sweeteners, such as aspartame, acesulfame potassium, sucralose and saccharin; and lubricants, such as magnesium stearate, stearic acid, talc, and waxes.
  • the dosage form may also incorporate pharmaceutical acceptable adjuvants. Such adjuvants, include, for example, preservatives, flavors, antioxidants, surfactants, and/or colors.
  • the tablets on a dry basis, generally comprise from about 0.1 to about 60, preferably about 12 to about 25, percent by weight of the active ingredient; from about 30 to about 90, preferably about 40 to about 65, percent by weight of the water-disintegratable, compressible carbohydrate material; from about 1 to about 30, preferably about 5 to about 20, percent by weight of the binder; from about 0.1 to about 5, preferably about 0.5 to about 1.5, percent by weight of the lubricant; from 0 to about 5, preferably about 0.1 to about 3.0, percent by weight of the sweetener; from 0 to about 5, preferably about 0.2 to about 2.0, percent by weight of the flavor; and from 0 to about 5, preferably about 0.01 to about 0.4, percent by weight of the color.
  • the unit weight of the tablet will vary depending on the dosage of the active ingredient.
  • the unit weight will generally range from about 250 to about 1000 mg.
  • a typical dosage form may contain:
  • Ingredient Unit Wt. (mg) Active Ingredient 0.5-600 Compressible Carbohydrate 80-900 Binder 10-200 Lubricant 1-15 Sweetener 0-30 Flavor 0-20 Color 0-10
  • coated particles of the active ingredient are prepared using the aforementioned techniques.
  • the particle size of the coated particles, as well as the remaining components, is generally less than 600 microns.
  • the components of the tablet are then dry mixed to form a uniform powder blend.
  • the blend is then compressed into a tablet of the desired hardness using conventional compression tableting techniques.
  • the compressed, chewable tablet has a convex or bi-convex shape and is relatively soft so as to provide good mouthfeel and taste and ease of chewing.
  • the tablet will have a diameter of about 7 to about 19, preferably about 9 to about 13,mm and a thickness of about 2 to about 12, preferably about 3 to about 8, mm.
  • FIGS. 1 a and 1 b are, top and side views, respectively, of a bi-convex tablet 10 of the present invention.
  • the tablet 10 has a pair of opposed face surfaces 12 and a side surface 14 .
  • the intersection of the face surfaces 12 with the side surface 14 defines the edges 16 .
  • the face surfaces 12 for the bi-convex tablet 10 have two radii of curvature, R 1 and R 2 .
  • the radius of curvature R 1 at the portion of the face surface 12 proximate to the edge 16 is about 0.7 to about 7.6, preferably about 2.36, mm.
  • the radius of curvature R 2 at the center of the tablet face 12 is about 7 to about 76, preferably about 25.2, mm.
  • the minor axis cup radius R 1 is about 10 % to about 40% of the tablet diameter, while the major axis cup radius R 2 is about 100% to about 400% of the tablet diameter.
  • the radius of curvature of the face surface of a simple convex tablet of the present invention (not shown) is about 5 to about 60 mm, which is about 75% to about 300% of the tablet diameter. Tri-convex tablets may also be used.
  • the external pressure applied by the tablet press during the compression step is controlled so that the hardness of the tablet is within the range of about 2 to about 11, preferably about 5 to about 8.5, kiloponds (kp) per sq. cm (cm 2 ).
  • Tablet breaking strength, or hardness is dependent on cross-sectional area at the tablet breaking point. In order to compare values across different size tablets, the breaking strength must be normalized for the area of the break. This normalized value, expressed in kp/cm 2 , is often referred in the art as tablet tensile strength.
  • Hardness is measure by conventional pharmaceutical hardness testing equipment, such as a Schleuniger Hardness Tester.
  • the compression forces in two steps.
  • a pre-compression pressure of about 2 to about 17, preferably about 5.5 to about 11.5, kN/cm 2 is applied.
  • the main compression pressure of about 3 to about 18, preferably about 7 to about 13, kN/cm 2 is then applied to complete the compression operation.
  • the tablet may be formed in one compression step using a compression pressure of about 3 to about 18, preferably about 7 to about 13, kN/cm 2 .
  • the compressed, chewable tablet has a friability of less than 1%, preferably less than 0.5%.
  • tablet friability is determined in accordance with USP Method ⁇ 1216> Tablet Friability, USP 23 (1995) and is expressed as percent weight loss. As shown in FIG. 2, as the hardness of a flat face, beveled edge tablet is reduced, friability increases. However, when the hardness of a concave tablet of the present decreases, friability remains substantially constant.
  • the tablets of the present invention can be compressed at lower compression forces, but still maintain acceptable friability. This results in a softer tablet having improved product taste, mouthfeel and ease of chewing. Compressing at reduced forces also reduces the probability of fracturing the coating used for masking the unpleasant taste of the active ingredient.
  • This Example provides a formulation for making a compressed, chewable bi-convex tablet containing acetaminophen coated with a blend of cellulose acetate and polyvinyl pyrrolidone.
  • the weights provided hereinafter are based on a tablet unit weight of 385 mg.
  • a coating solution containing a blend of cellulose acetate and polyvinyl pyrrolidone was prepared in accordance with U.S. Pat. No. 4,851,226 and applied to acetaminophen until coated acetaminophen particles containing approximately 11% by weight of coating were obtained.
  • the ratio of cellulose acetate to polyvinyl pyrrolidone was 85:15.
  • the coated acetaminophen particles were combined with following ingredients to produce the tablets:
  • Citric acid, aspartame, and color were combined with a portion of microcrystalline cellulose, and blended until a uniform distribution of color was obtained. This blend was then passed through a suitable comminutor.
  • Magnesium stearate and a portion of the mannitol were combined and passed through a suitable comminutor.
  • Thickness Target 4.5 mm
  • Example 2 describes the friability testing reported in FIG. 2 for the flat face, beveled edge (FFBE) tablet (control) and the concave tablet of the present invention.
  • the acetaminophen was coated with the taste masking coating described in Example I.
  • the coated acetaminophen particles were combined with following ingredients to produce the FFBE and concave tablets:
  • Unit Wt. (mg) Ingredients Concave FFBE CA/PVP Coated Acetaminophen 90.7 90.7 Mannitol (Granular), USP 241.55 226.55 Microcrystalline Cellulose, NF 30.0 30.0 Aspartame, NF 5.0 11.0 Acesulfame Potassium 6.0 — Color 0.35 0.35 Flavor 22.5 22.5 Magnesium Stearate, NF 3.9 3.9 Tablet Weight 400.0 385.0
  • Friabilty in wt % was then plotted against normalized hardness or tablet tensile strength in FIG. 2 .
  • Thickness (average of 5): 4.63 mm
  • a sensory preference test was conducted among 130 adults who tasted these tablets in comparison with Children's TYLENOL® 80 mg Acetaminophen Chewable Tablets (having an average hardness of 5.5 kp or 13.4 kp/cm 2 obtained from retail locations.
  • the tablets in this example were preferred over the commercial product by 77% of the participants, while 22% preferred the commercial product.
  • the tablets in this example were perceived as less bitter, more sweet, and having more pleasant taste and mouthfeel than the commercial product.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nutrition Science (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Physiology (AREA)
  • Zoology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to a compressed, chewable tablet containing at least one active ingredient, a water-disintegratable, compressible carbohydrate and a binder. These components are dry blended and compressed into convex-shaped tablet having a hardness of about 2 to about 11 kp/cm2 and friability less than 1%.

Description

FIELD OF THE INVENTION
The present invention relates to soft, convex-shaped compressed chewable tablets and a process for preparing such tablets.
BACKGROUND OF THE INVENTION
Chewable tablets are widely used in the pharmaceutical industry for patients, such as children, who have who have difficulty swallowing conventional tablets or capsules. Children's TYLENOL® Chewable Tables are an example of a pediatric chewable acetaminophen tablet sold in the United States. These tables are packaged in bottles and have a flat face, beveled edge shape. Samples of these tablets obtained from retail locations had hardnesses (average of ten tablets) ranging from 5.3-13.1 kp or normalized hardnesses of 12.3-30.5 kp/cm2.
Many comercially avaialable pediatric chewable tablets contain active ingredients which are coated with polymers to mask their unpleasant taste. However, the forces used to compress these tablets can fracture the polymer coatings, which reduces the effectiveness of the tastemasking system.
Rapidly disintegrating dosage forms, such as those described in U.S. Pat. No. 5,464,632, issued Nov. 7, 1995, are also available for patients, particularly aged and pediatric patients, having difficluties swallowing tablets and caplets. However, rapidly disintegrating dosage forms currently available are highly friable, and require the use of special handling and costly packaging, e.g., specially designed blister packs, to prevent breakage or chipping of the tablets. These limitations significantly increase the product cost.
Tablet shape also affects tablet friability. T. Chakrabarti et al. in The Indian Journal of Pharmacy, Vol. 38, No. 3, pp. 62-65 (1975) disclose that lower friability was observed in beveled flat tablets followed by standard convex and plain flat tablets. Similarily, K. Sugimori et al. in Powder Technology, Vol. 58, pp. 259-264 (1989) report that capping occurs more often in convex-shaped tablets than flat faced tablets.
A need, therefore, exists for compressed, chewable tablets having improved taste, but which exhibit low friability so that they may be processed with standard bulk handling equipment and packaged in bottles.
SUMMARY OF THE INVENTION
The present invention provides a compressed, chewable tablet containing at least one active ingredient, a water-disintegratable, compressible carbohydrate and a binder. These components are dry blended and compressed into a convex-shaped tablet having a hardness of about 2 to about 11 kp/cm2. The tablet has a friability of less than 1%.
In a preferred embodiment of the present invention, the compressed, chewable tablet is prepared by dry blending the active ingredient, water-disintegratable, compressible carbohydrate and binder, and then compressing into a convex-shaped tablet having a hardness of about 2 to about 11 kp/cm2. If the active ingredient has an objectionable taste, it is coated with a taste masking composition.
Compressing at reduced force reduces fracture of the coating used for masking the unpleasant taste of the active ingredient. These convex-shaped, chewable tablets are softer that conventional chewable tablets, which results in improvements in product taste, mouthfeel, and ease of chewing.
The convex tablet geometry significantly reduces tablet friability at a given compression force. This reduction in tablet friability allows for the use of lower compression forces and lower tablet hardness, while maintaining the ability to process the tablets with conventional bulk handling equipment and package them in conventional bottles.
BRIEF DESCRIPITON OF THE DRAWINGS
FIGS. 1a and 1 b are front and side views, respectively, of a bi-convex tablet of the present invention.
FIG. 2 is a graph of friability (wt % loss) vs. hardness (kp/cm2) for a flat face, beveled edge tablet (control) and a concave tablet of the present invention.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
The compressed, chewable tablets of the present invention comprise at least one active ingredient, a water-disintegratable, compressible carbohydrate, and a binder. These ingredients are dry blended and then compressed into a convex-shaped tablet having a hardness of about 2 to about 11, preferably about 5 to about 8.5, kp/cm2. Tablet friability is also preferably less than 1%.
Tableting machines, preferably those capable of applying separate pre-compression and main compression forces, are used to compress the ingredients into tablets. Since the ingredients are dry blended, water-soluble, as well as water-insoluble, active ingredients can be used in the tablet. If the active ingredients have an objectionable taste they may be coated with a taste masking composition.
The water-disintegratable, compressible carbohydrate used in the present invention includes carbohydrate materials conventionally used in tablets. The carbohydrates facilitate the breakup of the dosage form after oral administration, and are described in Lieberman et al., Pharmaceutical Dosage Forms, Marcel Dekker, Inc., New York, 2 Ed. Vol. 1, pp. 205-209 (1990), which is hereby incorporated by reference. Preferred water-disintegratable, compressible carbohydrates include mannitol, sorbitol, maltitol, dextrose, sucrose, xylitol, lactose, and mixtures thereof.
The binder in the present invention is used to add cohesiveness to the formulation, thereby providing the necessary bonding to form a cohesive mass or compact upon compression. These binders are conventionally used in direct compression tablets and are described in Lieberman et al., Pharmaceutical Dosage Forms, 2 Ed., Vol. 1, pp. 209-214 (1990), which is hereby incorporated by reference. Preferred binders include cellulose, cellulosic derivatives, polyvinyl pyrrolidone, starch, modified starch, and mixtures thereof, and, in particular, microcrystalline cellulose available from FMC Corp. under the trademark AVICEL® PH 101.
The tablets of the present invention are used to orally administer a wide variety of active ingredients. Suitable active ingredients include pharmaceuticals, minerals, vitamins and other nutraceuticals. Suitable pharmacuticals include analgesics, decongestants, expectorants, antitussives, antihistamines, gastrointestinal agents, diuretics, bronchodilators, sleep-inducing agents and mixtures thereof. Preferred pharmaceuticals include acetaminophen, ibuprofen, flurbiprofen, naproxen, aspirin, pseudoephedrine, phenylpropanolamine, chlorpheniramine maleate, dextromethorphan, diphenhydramine, famotidine, loperamide, ranitidine, cimetidine, astemizole, terfenadine, terfenadine carboxylate, cetirizine, mixtures thereof and pharmaceutically acceptable salts thereof.
The active ingredients are present in the tablet in a therapeutic effective amount, which is an amount that produces the desired therapeutic response upon oral administration and can be readily determined by one skilled in the art. In determining such amounts, the particular compound being administered, the bioavailability characteristics of the ingredient, the dose regime, the age and weight of the patient, and other factors must be considered.
If the active ingredient has an objectionable taste, a coated particle containing the active ingredient coated with a taste masking coating is employed. The active may be coated with taste masking coatings known in the art, such as those described in U.S. Pat. No. 4,851,226, issued Jul. 25, 1989, to T. W. Julian, et al.; U.S. Pat. No. 5,075,114, issued Dec. 24, 1991 to E. J. Roche; and U.S. Pat. No. 5,489,436, issued Feb. 6, 1996, all of which are hereby incorporated by reference. Commercially available taste masked active ingredients may also be employed. For example, acetaminophen particles which are encapsulated with ethylcellulose or other polymers by a coaccervation process may be used in the present invention. Coaccervation-encapsulated acetaminophen may be purchased commercially from Eurand America, Inc. Vandalia, Ohio, or from Circa Inc., Dayton, Ohio.
As used in the present invention, “coated particle” refers to a solid active ingredient in the form of a crystal or particle, an agglomerate of individual particles, or a granuled particle, which has been encapsulated with a the taste masking composition, either by film coating or by another process such as coaccervation. The tablet may provide for immediate or sustained release of the active.
Taste masking compositions suitable for use as coatings are provided in the following table:
Polymer System Coat Level1 Polymer Ratio2
Cellulose Acetate/PVP 5-60% 90/10 to 60/40
Cellulose Acetate 5-60% 90/10 to 60/40
Butyrate/PVP
Cellulose Acetate/HPC 5-60% 90/10 to 50/50
Cellulose Acetate 5-60% 90/10 to 50/50
Butyrate/HPC
Cellulose Acetate/ 8-60% All ratios
EUDRAGIT E100
Cellulose Acetate Butyrate/ 8-60% All ratios
EUDRAGIT E100
Ethyl Cellulose/PVP 8-60% 90/10 to 60/40
Ethyl Cellulose/HPC 8-60% 90/10 to 50/50
Ethyl Cellulose/ 8-60% All ratios
EUDRAGIT E100
HPC 10-60% NA
HEC 10-60% NA
EUDRAGIT E100 10-60% NA
HPMC 10-60% NA
HEC/HPMC 10-60% All ratios
HPC/HPMC 10-60% All ratios
HEC/HPC 10-60% All ratios
2-vinyl pyrridine styrene 10-60% NA
co-polymer
CA/2-vps 8-60% All ratios
CAB/2-vps 8-60% All ratios
Ethyl Cellulose/2-vps 8-60% All ratios
Cellulose Triacetate/PVP 8-60% 90/10 to 60/40
Cellulose Triacetate/HPC 8-60% 90/10 to 50/50
Cellulose Triacetate/ 8-60% All ratios
EUDRAGIT E100
1Percent by weight of the coated particle in a dried state.
2By weight.
PVP — polyvinylpyrrolidone
HPC — Hydroxypropyl cellulose
HEC — Hydroxyethyl cellulose
HPMC — Hydroxypropylmethyl cellulose
CA — Cellulose Acetate
CAB — Cellulose Acetate Butyrate
2-VPS — 2-Vinyl pyridine styrene
EUDRAGIT ™ E-100 — methylaminoethyl-methacrylate and neutral methacrylic acid esters available from Rohm Pharma GmbH, Germany.
Substantially all of the active ingredient or granulated active ingredient should be coated with a layer of a taste masking composition having a thickness of about 3 to about 10 microns. The coating should be substantially free of cracks, holes or other imperfections when examined under a scanning electron microscope at 100-500×.
If taste masking is necessary, the active ingredient is preferably coated with a blend of a first polymer selected from the group consisting of cellulose acetate and cellulose acetate butyrate and a second polymer selected from the group consisting of polyvinyl pyrrolidone and hydroxypropyl cellulose. The weight ratio of the first polymer to the second polymer in this blend is within the range of about 90:10 to about 50:50 and preferably about 90:10 to about 70:30.
The blend of first and second polymers may be coated directly onto the pure active ingredient or may be coated onto a granulated particle containing the active. In the case of a granulated particle, such as a rotogranulated particle, the active will constitute from about 5 to about 90 weight percent of the particle, with the remainder being the binder or filler. Suitable binders for the granulated particles include polyvinyl pyrrolidone, hydroxypropylmethyl cellulose, hydroxypropyl cellulose, and other pharmaceutically acceptable polymers. Fillers suitable for use in such granulated particles include lactose, confectioner's sugar, mannitol, dextrose, fructose, other pharmaceutically acceptable saccharides and microcrystalline cellulose.
The coated particles may be prepared by spraying an organic solvent solution of the polymeric blend onto the active ingredient, or a granulated particle containing the active ingredient, in a fluidized bed, such as a Wurster coater or a rotogranulator. A wide variety of organic solvents may be used to prepare the solution of the polymeric blend. For example, a preferred solvent is a mixture of acetone and methanol, but other solvent systems may be employed, including methylene chloride, methylene chloride-methanol, acetone-ethyl acetate, toluene-ethanol and acetone-ethanol. Generally, the proportion of the polymer blend in the solvent solution will be within the range of about 5 to about 20, preferably about 8 to about 15, weight percent, depending on the solvent and other similar considerations.
When a fluidized bed coating operation is used, air, which may be heated, passes through a bed of the active ingredient solids to fluidize them, and the solution of the polymeric blend is sprayed onto the fluidized bed and thereby coats the active. The air passing through the bed dried the coating onto the active ingredient, so that a dry coated granule is obtained.
Conventional fluidized bed coating equipment may be used in the present invention to coat the active ingredient or the rotogranulated particle containing the pharmaceutical. This equipment includes Wurster fluid-bed coaters, where the solution of the polymer blend is sprayed from the bottom of the chamber, and a rotogranulator, where the solution of the polymer blend is tangentially sprayed. These coating operations are further described in Lieberman et al., Pharmaceutical Dosage Forms, Marcel Dekker, Inc., New York, Vol. 3, pp. 138-150 (1990), which is hereby incorporated by reference.
The coated particle, in a dried state, generally contains about 5 to about 60, preferably about 10 to 40, weight percent of the blend of the first and second polymers. The exact proportions of the coating to the active ingredient can, however, vary depending upon the level of taste masking required and whether a sustained or immediate release of the active is desired. Larger proportions of the coating tend to provide a sustained release effect and enhance taste masking.
The tablet may also contain ingredients other than the coated particles, carbohydrate and binder. The additional ingredients include sweeteners, such as aspartame, acesulfame potassium, sucralose and saccharin; and lubricants, such as magnesium stearate, stearic acid, talc, and waxes. The dosage form may also incorporate pharmaceutical acceptable adjuvants. Such adjuvants, include, for example, preservatives, flavors, antioxidants, surfactants, and/or colors.
The tablets, on a dry basis, generally comprise from about 0.1 to about 60, preferably about 12 to about 25, percent by weight of the active ingredient; from about 30 to about 90, preferably about 40 to about 65, percent by weight of the water-disintegratable, compressible carbohydrate material; from about 1 to about 30, preferably about 5 to about 20, percent by weight of the binder; from about 0.1 to about 5, preferably about 0.5 to about 1.5, percent by weight of the lubricant; from 0 to about 5, preferably about 0.1 to about 3.0, percent by weight of the sweetener; from 0 to about 5, preferably about 0.2 to about 2.0, percent by weight of the flavor; and from 0 to about 5, preferably about 0.01 to about 0.4, percent by weight of the color.
The unit weight of the tablet will vary depending on the dosage of the active ingredient. The unit weight will generally range from about 250 to about 1000 mg. A typical dosage form may contain:
Ingredient Unit Wt. (mg)
Active Ingredient 0.5-600 
Compressible Carbohydrate 80-900
Binder 10-200
Lubricant 1-15
Sweetener 0-30
Flavor 0-20
Color 0-10
If taste masking is required, coated particles of the active ingredient are prepared using the aforementioned techniques. The particle size of the coated particles, as well as the remaining components, is generally less than 600 microns. The components of the tablet are then dry mixed to form a uniform powder blend. The blend is then compressed into a tablet of the desired hardness using conventional compression tableting techniques.
In a preferred embodiment of the invention, the compressed, chewable tablet has a convex or bi-convex shape and is relatively soft so as to provide good mouthfeel and taste and ease of chewing. Generally, the tablet will have a diameter of about 7 to about 19, preferably about 9 to about 13,mm and a thickness of about 2 to about 12, preferably about 3 to about 8, mm.
FIGS. 1a and 1 b are, top and side views, respectively, of a bi-convex tablet 10 of the present invention. The tablet 10 has a pair of opposed face surfaces 12 and a side surface 14. The intersection of the face surfaces 12 with the side surface 14 defines the edges 16. The face surfaces 12 for the bi-convex tablet 10 have two radii of curvature, R1 and R2. The radius of curvature R1 at the portion of the face surface 12 proximate to the edge 16 (minor axis cup radius) is about 0.7 to about 7.6, preferably about 2.36, mm. The radius of curvature R2 at the center of the tablet face 12 (major axis cup radius) is about 7 to about 76, preferably about 25.2, mm. Alternatively, the minor axis cup radius R1 is about 10 % to about 40% of the tablet diameter, while the major axis cup radius R2 is about 100% to about 400% of the tablet diameter. The radius of curvature of the face surface of a simple convex tablet of the present invention (not shown) is about 5 to about 60 mm, which is about 75% to about 300% of the tablet diameter. Tri-convex tablets may also be used.
The external pressure applied by the tablet press during the compression step is controlled so that the hardness of the tablet is within the range of about 2 to about 11, preferably about 5 to about 8.5, kiloponds (kp) per sq. cm (cm2). Tablet breaking strength, or hardness, is dependent on cross-sectional area at the tablet breaking point. In order to compare values across different size tablets, the breaking strength must be normalized for the area of the break. This normalized value, expressed in kp/cm2, is often referred in the art as tablet tensile strength. Hardness is measure by conventional pharmaceutical hardness testing equipment, such as a Schleuniger Hardness Tester.
During tableting it is preferable to apply the compression forces in two steps. A pre-compression pressure of about 2 to about 17, preferably about 5.5 to about 11.5, kN/cm2 is applied. The main compression pressure of about 3 to about 18, preferably about 7 to about 13, kN/cm2 is then applied to complete the compression operation. Alternatively, the tablet may be formed in one compression step using a compression pressure of about 3 to about 18, preferably about 7 to about 13, kN/cm2.
The compressed, chewable tablet has a friability of less than 1%, preferably less than 0.5%. In the present invention, tablet friability is determined in accordance with USP Method <1216> Tablet Friability, USP 23 (1995) and is expressed as percent weight loss. As shown in FIG. 2, as the hardness of a flat face, beveled edge tablet is reduced, friability increases. However, when the hardness of a concave tablet of the present decreases, friability remains substantially constant. These findings are unexpected in view of the friability reported by Chakrabarti et al. and Sugimori et al., supra, for convex tablets.
These findings are significant because the tablets of the present invention can be compressed at lower compression forces, but still maintain acceptable friability. This results in a softer tablet having improved product taste, mouthfeel and ease of chewing. Compressing at reduced forces also reduces the probability of fracturing the coating used for masking the unpleasant taste of the active ingredient.
Specific embodiments of the present invention are illustrated by way of the following examples. This invention is not confined to the specific limitations set forth in these examples, but rather to the scope of the appended claims. Unless otherwise stated, the percentages and ratios given below are by weight.
EXAMPLE I
This Example provides a formulation for making a compressed, chewable bi-convex tablet containing acetaminophen coated with a blend of cellulose acetate and polyvinyl pyrrolidone. The weights provided hereinafter are based on a tablet unit weight of 385 mg.
A coating solution containing a blend of cellulose acetate and polyvinyl pyrrolidone was prepared in accordance with U.S. Pat. No. 4,851,226 and applied to acetaminophen until coated acetaminophen particles containing approximately 11% by weight of coating were obtained. The ratio of cellulose acetate to polyvinyl pyrrolidone was 85:15.
The coated acetaminophen particles were combined with following ingredients to produce the tablets:
Ingredients Unit Wt. (mg)
CA/PVP Coated Acetaminophen Particles 89.9
Mannitol (Granular), USP 246.03
Microcrystalline Cellulose, NF 30.0
Aspartame, NF 9.0
Color 1.27
Citric Acid, USP 2.1
Flavor 2.3
Magnesium Stearate, NF 4.4
Tablet weight 385.0
Procedure
1. Citric acid, aspartame, and color were combined with a portion of microcrystalline cellulose, and blended until a uniform distribution of color was obtained. This blend was then passed through a suitable comminutor.
2. Magnesium stearate and a portion of the mannitol were combined and passed through a suitable comminutor.
3. The remaining mannitol was passed through a suitable comminutor and then discharged into a blender.
4. The blends from 1 and 2 above, flavor, coated acetaminophen, and the remainder of the microcrystalline cellulose were added to the blender, and blended until uniform distribution of active ingredient was achieved.
5. The blend was compressed into bi-concave tablets to the following specifications on a Fette Model 3090 rotary tablet press:
Punches: 10.3 mm diameter, bi-concave having a minor axis cup radius of curvature of 2.36 mm and a major axis cup radius of curvature of 25.2 mm
Pre-compression Force: 7.4-8.1 kN (8.5-9.4 kN/cm2)
Main Compression Force: 8.4-9.1 kN (9.7-10.6 kN/cm2)
Thickness: Target 4.5 mm
Weight: Target 385 mg
Friability*: Target 0.14
The following measurments were made on the tablets:
Physical Property Average of 5 Individuals
Weight (mg) 382-389 379-391
Hardness (kp/cm2) 6.0-7.4 5.2-8.3
Thickness (mm) 4.44-4.49 4.43-4.52
Friability* — 0.11-0.18
*(% wt. loss, 20 tablets)
Bulk tablets were successfully transported between Puerto Rico and New Jersey in 19-gallon fiber drums containing approximately 30 kg of tablets per drum.
EXAMPLE II
This Example describes the friability testing reported in FIG. 2 for the flat face, beveled edge (FFBE) tablet (control) and the concave tablet of the present invention. The acetaminophen was coated with the taste masking coating described in Example I.
The coated acetaminophen particles were combined with following ingredients to produce the FFBE and concave tablets:
Unit Wt. (mg)
Ingredients Concave FFBE
CA/PVP Coated Acetaminophen 90.7 90.7
Mannitol (Granular), USP 241.55 226.55
Microcrystalline Cellulose, NF 30.0 30.0
Aspartame, NF 5.0 11.0
Acesulfame Potassium 6.0 —
Color 0.35 0.35
Flavor 22.5 22.5
Magnesium Stearate, NF 3.9 3.9
Tablet Weight 400.0 385.0
The ingredients were blended and compressed into tablets on a Manesty Betapress at different hardness levels by changing the compression forces. The following specifications were used:
Concave
Punches: Round, no land, standard concave 13/32 inch (10.3 mm)×0.038 inch cup depth
Hardness Range: 1.5-6.0 kp
Weight(10 tablets): 4.0 g (Range 3.85-4.15 g)
FFBE
Punches: 10 mm round flat faced, beveled edge
Hardness Range: 1.5-6.0 kp
Weight (10 tablets): 3.85 g (Range 3.75-3.95 g)
The friability of the tablets was measured in accordance with Tablet Friability <1216>, USP 23 (1995). Friabilty in wt % was then plotted against normalized hardness or tablet tensile strength in FIG. 2.
EXAMPLE III
Tastemasked acetaminophen particles, prepared in the manner described in Example I, were combined with the following ingredients to produce compressed, chewable tablets, using the process described below:
Ingredients Unit Wt. (mg)
CA/PVP Coated Acetaminophen Particles 90.7
Mannitol (Granular), USP 243 96
Microcrystalline Cellulose, NF 30.0
Aspartame, NF 11.0
Color 0.04
Citric Acid, USP 2.1
Flavor 3.3
Magnesium Stearate, NF 3.9
Tablet Weight 385.0
Procedure
1. All ingredients except magnesium stearate were combined in a PK blender, and blended for 10 minutes. The magnesium stearate was added to the blender and blending was continued for an additional 5 minutes.
2. Tablets were compressed to the following specifications on a Manesty Betapress using 13/32-inch diameter, round bi-concave tooling having 2.36 mm minor axis cup radius and 25.2 mm major axis cup radius:
Target
Pre-compression Force 0-0.1 kN (0-0.12 kN/cm2)
Main compression Force 6.5-6.9 kN (7.5-8.0 kN/cm2)
Weight (average of 10): 385 mg
Thickness (average of 5): 4.63 mm
Hardness (average of 5): 3.0 kp(6.5 kp/cm2)
The following measurements were made on the tablets:
Physical Property Range
Weight (average of 10) 383.5-386.7 mg
Hardness (average of 5) 2.90-3.06 kp
(6.27-6.61 kp/cm2)
Thickness (average of 5) 4.62-4.66 mm
A sensory preference test was conducted among 130 adults who tasted these tablets in comparison with Children's TYLENOL® 80 mg Acetaminophen Chewable Tablets (having an average hardness of 5.5 kp or 13.4 kp/cm2 obtained from retail locations. The tablets in this example were preferred over the commercial product by 77% of the participants, while 22% preferred the commercial product. The tablets in this example were perceived as less bitter, more sweet, and having more pleasant taste and mouthfeel than the commercial product.
Various modifications can be made from the above-described embodiments without departing from the spirit and scope of the present invention.

Claims (8)

What is claimed is:
1. A compressed, chewable tablet having opposed major surfaces, comprising:
about 0.1 to about 60% of at least one active ingredient coated with a taste masking coating;
about 30 to about 90% of a water-disintegratable, compressible carbohydrate selected form the group consisting of mannitol, sorbitol, maltitol, dextrose, sucrose, xylitol, lactose, and mixtures thereof;
about 1 to about 30% of a binder selected form the group consisting of cellulose, cellulosic derivatives, polyvinyl pyrrolidone, starch, modified starch and mixtures thereof;
about 0.1 to about 5% of a lubricant;
0 to about 5% sweetener;
0 to about 5% flavor;
0 to about 5% color, by weight of said tablet; and
said face surfaces having a convex shape and said tablet having a hardness of about 2 to about 11 kp/cm2 and a friability of less than about 1%.
2. The tablet of claim 1 having a hardness of about 5 to about 8.5 kp/cm2.
3. The tablet of claim 1 having a friability of less than about 0.5%.
4. The tablet of claim 1 wherein said face surfaces have a bi-convex or tri-convex shape.
5. The tablet of claim 4 having bi-convex shaped face surfaces and a minor axis cup radius of about 10 to about 40 percent of the tablet diameter and major axis cup radius of about 100 to about 400 percent of the tablet diameter.
6. The tablet of claim 1 wherein said coated active ingredient comprises at least one active ingredient coated with a blend of a first polymer selected from the group consisting of a cellulose acetate and cellulose acetate butyrate and a second polymer selected from the group consisting of polyvinyl pyrrolidone and hydroxypropyl cellulose, wherein the weight ratio of the first polymer to the second polymer is within the range of about 90:10 to about 50:50.
7. The tablet of claim 6 wherein the coated active ingredient comprises about 5 to about 60 percent by weight of the blend of first and second polymers.
8. The tablet of claim 1 wherein the active ingredient is selected from the group consisting of acetaminophen, ibuprofen, flurbiprofen, naproxen, aspirin, pseudoephedrine, phenylpropanolamine, chlorpheniramine maleate, dextromethorphan, diphenhydramine, famotidine, loperamide, ranitidine, cimetidine, astemizole, terfenadine, terfenadine carboxylate, cetirizine, mixtures thereof and pharmaceutically acceptable salts thereof.
US09/135,723 1998-08-18 1998-08-18 Soft, convex shaped chewable tablets having reduced friability Expired - Lifetime US6270790B1 (en)

Priority Applications (19)

Application Number Priority Date Filing Date Title
US09/135,723 US6270790B1 (en) 1998-08-18 1998-08-18 Soft, convex shaped chewable tablets having reduced friability
PT99306455T PT997143E (en) 1998-08-18 1999-08-17 Soft chewable tablets
AT99306455T ATE381320T1 (en) 1998-08-18 1999-08-17 SOFT CHEWABLE TABLET
KR1019990033896A KR20000017352A (en) 1998-08-18 1999-08-17 Soft chewable tablets
DE69937780T DE69937780T2 (en) 1998-08-18 1999-08-17 Soft chewable tablet
EP99306455A EP0997143B1 (en) 1998-08-18 1999-08-17 Soft chewable tablets
CA002280628A CA2280628C (en) 1998-08-18 1999-08-17 Soft chewable tablets
ZA9905248A ZA995248B (en) 1998-08-18 1999-08-17 Soft chewable tablets.
ES99306455T ES2299234T3 (en) 1998-08-18 1999-08-17 SOFT CHEATABLE TABLETS.
BR9903736-0A BR9903736A (en) 1998-08-18 1999-08-18 Soft chewable tablets
CN99119112A CN1249176A (en) 1998-08-18 1999-08-18 Soft chew tablet
AU44565/99A AU773549B2 (en) 1998-08-18 1999-08-18 Soft chewable tablets
ARP990104128A AR022065A1 (en) 1998-08-18 1999-08-18 SOFT CHEATABLE TABLETS
NZ337310A NZ337310A (en) 1998-08-18 1999-08-18 Compressed chewable tablet comprising active ingredient, carbohydrate and binder, process of preparation
JP11232034A JP2000095673A (en) 1998-08-18 1999-08-18 Flexible and chewable tablets
CO99052293A CO5130019A1 (en) 1998-08-18 1999-08-18 COMPRESSED SOFT CHEATABLE TABLETS AND CONVEX AND PROCESS FOR PREPARATION
SA99200655A SA99200655B1 (en) 1998-08-18 1999-10-10 Chewable soft tablets
US09/880,179 US6471991B2 (en) 1998-08-18 2001-06-13 Soft chewable tablets having convexed shaped face surfaces
US10/226,540 US7029699B2 (en) 1998-08-18 2002-08-22 Soft chewable tablets

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/135,723 US6270790B1 (en) 1998-08-18 1998-08-18 Soft, convex shaped chewable tablets having reduced friability

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US09/880,179 Continuation US6471991B2 (en) 1998-08-18 2001-06-13 Soft chewable tablets having convexed shaped face surfaces
US10/226,540 Continuation US7029699B2 (en) 1998-08-18 2002-08-22 Soft chewable tablets

Publications (1)

Publication Number Publication Date
US6270790B1 true US6270790B1 (en) 2001-08-07

Family

ID=22469364

Family Applications (3)

Application Number Title Priority Date Filing Date
US09/135,723 Expired - Lifetime US6270790B1 (en) 1998-08-18 1998-08-18 Soft, convex shaped chewable tablets having reduced friability
US09/880,179 Expired - Lifetime US6471991B2 (en) 1998-08-18 2001-06-13 Soft chewable tablets having convexed shaped face surfaces
US10/226,540 Expired - Lifetime US7029699B2 (en) 1998-08-18 2002-08-22 Soft chewable tablets

Family Applications After (2)

Application Number Title Priority Date Filing Date
US09/880,179 Expired - Lifetime US6471991B2 (en) 1998-08-18 2001-06-13 Soft chewable tablets having convexed shaped face surfaces
US10/226,540 Expired - Lifetime US7029699B2 (en) 1998-08-18 2002-08-22 Soft chewable tablets

Country Status (17)

Country Link
US (3) US6270790B1 (en)
EP (1) EP0997143B1 (en)
JP (1) JP2000095673A (en)
KR (1) KR20000017352A (en)
CN (1) CN1249176A (en)
AR (1) AR022065A1 (en)
AT (1) ATE381320T1 (en)
AU (1) AU773549B2 (en)
BR (1) BR9903736A (en)
CA (1) CA2280628C (en)
CO (1) CO5130019A1 (en)
DE (1) DE69937780T2 (en)
ES (1) ES2299234T3 (en)
NZ (1) NZ337310A (en)
PT (1) PT997143E (en)
SA (1) SA99200655B1 (en)
ZA (1) ZA995248B (en)

Cited By (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020122823A1 (en) * 2000-12-29 2002-09-05 Bunick Frank J. Soft tablet containing dextrose monohydrate
US20030049316A1 (en) * 1998-08-18 2003-03-13 Robinson Ronni L. Soft chewable tablets
US20030068373A1 (en) * 2001-09-28 2003-04-10 Joseph Luber Immediate release tablet
US20030096791A1 (en) * 2001-05-31 2003-05-22 Cima Labs Inc. Taste masking of highly water-soluble drugs
US20030109565A1 (en) * 2001-12-10 2003-06-12 Daniel Wils Antipyretic preparation containing xylitol
US20030215502A1 (en) * 2002-03-20 2003-11-20 Elan Pharma International Limited Fast dissolving dosage forms having reduced friability
US20040170690A1 (en) * 2001-06-28 2004-09-02 Domenico Fanara Tablet comprising cetirizine and pseudoephedrine
US6790980B1 (en) 2001-08-31 2004-09-14 First Horizon Pharmaceutical Corporation Tannate compositions and methods of treatment
US20050226908A1 (en) * 2004-04-07 2005-10-13 Akzo Nobel N.V. Efficacious composition of a benzimidazole, an avermectin and praziquantel and related methods of use
WO2006058022A1 (en) 2004-11-24 2006-06-01 Medpointe Healthcare Inc. Compositions comprising azelastine and methods of use thereof
US7282217B1 (en) * 2003-08-29 2007-10-16 Kv Pharmaceutical Company Rapidly disintegrable tablets
US20080161417A1 (en) * 2005-05-08 2008-07-03 Li Zhao Xylitol Granules Capable of Directly Being Compressible Into Tablets and Preparation Process Thereof
US20080181932A1 (en) * 2007-01-30 2008-07-31 Drugtech Corporation Compositions for oral delivery of pharmaceuticals
US7482022B2 (en) 2002-04-04 2009-01-27 Pfizer Inc. Palatable chewable tablet
WO2009020268A1 (en) 2007-08-03 2009-02-12 Choongwae Pharma Corporation Composition for manufacturing orally disintegrating dosage form to protect coating layer of active substance
US20090191267A1 (en) * 2005-09-30 2009-07-30 Wynn David W Oral Compositions Containing a Salivation Inducing Agent
US20090258039A1 (en) * 2002-12-04 2009-10-15 Bunick Frank J Method of administering a pharmaceutical active ingredient
US7635490B2 (en) 2001-09-28 2009-12-22 Mcneil-Ppc, Inc. Modified release dosage form
US20100190739A1 (en) * 2008-12-15 2010-07-29 Fleming And Company, Pharmaceuticals Rapidly Dissolving Vitamin Formulation and Methods of Using the Same
US7838026B2 (en) 2001-09-28 2010-11-23 Mcneil-Ppc, Inc. Burst-release polymer composition and dosage forms comprising the same
EP2314171A1 (en) 2002-08-13 2011-04-27 Intervet International BV Compositions and process for delivering an additive
US8114328B2 (en) 2001-09-28 2012-02-14 Mcneil-Ppc, Inc. Method of coating a dosage form comprising a first medicant
WO2013068371A1 (en) 2011-11-08 2013-05-16 Intervet International B.V. Soft chewable dosage form compositions of cannabinoid receptor type 1 (cb-1) antagonists
WO2013119442A1 (en) 2012-02-06 2013-08-15 Merial Limited Parasiticidal oral veterinary compositions comprising systemically-acting active agents, methods and uses thereof
US8758816B2 (en) 2004-11-24 2014-06-24 Meda Pharmaceuticals Inc. Compositions comprising azelastine and methods of use thereof
WO2016033424A1 (en) 2014-08-29 2016-03-03 Genzyme Corporation Methods for the prevention and treatment of major adverse cardiovascular events using compounds that modulate apolipoprotein b
WO2016134846A1 (en) 2015-02-27 2016-09-01 Rottapharm Ltd. Composition for the treatment of acne
WO2017008909A1 (en) 2015-07-16 2017-01-19 Rottapharm S. P. A. Oral formulation comprising berberine and morus alba extract
US10064817B2 (en) 2004-11-24 2018-09-04 Meda Pharmaceuticals Inc. Compositions comprising azelastine and methods of use thereof
US10117831B2 (en) 2015-12-19 2018-11-06 First Time Us Generics Llc Soft chew pharmaceutical formulations
JPWO2019004155A1 (en) * 2017-06-27 2020-04-23 第一三共株式会社 tablet
US11285101B2 (en) 2012-04-04 2022-03-29 Intervet Inc. Soft chewable pharmaceutical products
WO2022133420A1 (en) 2020-12-18 2022-06-23 Boehringer Ingelheim Animal Health USA Inc. Boron containing pyrazole compounds, compositions comprising them, methods and uses thereof
IT202100016310A1 (en) * 2021-06-22 2022-12-22 Alaia Idea S R L Method for making tablets
US20230123099A1 (en) * 2021-10-15 2023-04-20 Fertin Pharma A/S Dextrose tablets with improved mouthfeel
US11633361B2 (en) 2015-12-19 2023-04-25 First Time Us Generics Llc Soft chew pharmaceutical formulations

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040081697A1 (en) * 1998-11-12 2004-04-29 Smithkline Beecham P.L.C. Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
US20040102486A1 (en) * 1998-11-12 2004-05-27 Smithkline Beecham Corporation Novel method of treatment
KR100446153B1 (en) * 2001-10-24 2004-08-30 한국유나이티드제약 주식회사 Formulation of a soluble ibuprofen and its process
FR2831820B1 (en) * 2001-11-05 2004-08-20 Ethypharm Sa ORODISPERSIBLE TABLET HAVING HIGH HOMOGENEITY AND PREPARATION METHOD THEREOF
WO2004050023A2 (en) 2002-11-27 2004-06-17 Dmi Biosciences, Inc. Treatment of diseases and conditions mediated by increased phosphorylation
US20040265372A1 (en) * 2003-06-27 2004-12-30 David Wynn Soft tablet containing high molecular weight cellulosics
US20040265373A1 (en) * 2003-06-27 2004-12-30 David Wynn Soft tablet containing high molecular weight cellulosics
SI1660104T1 (en) * 2003-08-26 2010-08-31 Shire Holdings Ag Pharmaceutical formulation comprising lanthanum compounds
WO2005030083A2 (en) * 2003-09-25 2005-04-07 Dmi Biosciences Inc. Methods and products which utilize n-acyl-l-aspartic acid
US20050095299A1 (en) * 2003-10-30 2005-05-05 Wynn David W. Controlled release analgesic suspensions
US20050095300A1 (en) * 2003-10-30 2005-05-05 Wynn David W. Controlled release analgesic suspensions
US7201920B2 (en) 2003-11-26 2007-04-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of opioid containing dosage forms
WO2007007659A1 (en) * 2005-07-08 2007-01-18 Takeda Pharmaceutical Company Limited Tablet
US20070020186A1 (en) * 2005-07-22 2007-01-25 Alpex Pharma S.A. Solid dosage formulations of narcotic drugs having improved buccal adsorption
US20070128251A1 (en) * 2005-12-07 2007-06-07 Piedmont Pharmaceuticals, Inc. Process for manufacturing chewable dosage forms for drug delivery and products thereof
GB0601498D0 (en) 2006-01-25 2006-03-08 Probio Nutraceuticals As Product
ZA200807571B (en) 2006-03-01 2009-08-26 Ethypharm Sa Crush-resistant tablets intended to prevent accidental misuse and unlawful diversion
US20070251352A1 (en) * 2006-05-01 2007-11-01 Pruitt Judith G Pelletized Feed Material for Biomass Generator
US20090269393A1 (en) * 2006-06-12 2009-10-29 Jubliant Organosys Limited Chewable Bilayer Tablet Formulation
USD616032S1 (en) * 2007-08-24 2010-05-18 Maraia Micah L Clip for identifying elongated objects
US8771643B2 (en) 2008-01-04 2014-07-08 Schabar Research Associates Llc Use of analgesic potentiating compounds to potentiate the analgesic properties of an analgesic compound
US20100009012A1 (en) * 2008-07-11 2010-01-14 Zukkoor N David Chewable pharyngeal inflammation symptom relief composition
US20100278913A1 (en) * 2009-04-30 2010-11-04 Sancilio & Company Chewable tablet
USD685460S1 (en) * 2009-08-27 2013-07-02 Astrazeneca Ab Tablet
AU2010300641B2 (en) 2009-09-30 2016-03-17 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse
CA2783877A1 (en) * 2009-12-10 2011-06-16 A. Mark Schobel Ph sensitive compounds in taste masking within oral thin film strips
USD636070S1 (en) * 2010-02-26 2011-04-12 Astrazeneca Ab Tablet
USD632386S1 (en) * 2010-06-01 2011-02-08 Herbalife International of America Oral supplement
JP5771381B2 (en) * 2010-10-22 2015-08-26 アサヒフードアンドヘルスケア株式会社 Tablet containing dry yeast
USD697510S1 (en) * 2011-03-23 2014-01-14 Brother Industries, Ltd. Scanner with projector
WO2014033230A1 (en) 2012-08-31 2014-03-06 Friulchem Spa Compositions for oral administration to animals, production methods thereof and uses of same
BR112014005909B1 (en) 2011-09-15 2021-05-18 Friulchem Spa compositions for oral administration to animals, methods of production thereof and uses thereof
PL2861236T3 (en) 2012-06-15 2020-03-31 Pharmathen S.A. Pharmaceutical composition containing phosphate binding polymer
US9532946B2 (en) * 2012-11-20 2017-01-03 Intervet Inc. Manufacturing of semi-plastic pharmaceutical dosage units
AU2013352162B2 (en) 2012-11-30 2018-08-16 Acura Pharmaceuticals, Inc. Self-regulated release of active pharmaceutical ingredient
WO2015145461A1 (en) 2014-03-26 2015-10-01 Sun Pharma Advanced Research Company Ltd. Abuse deterrent immediate release biphasic matrix solid dosage form
CN104490804A (en) * 2014-12-05 2015-04-08 海南卫康制药(潜山)有限公司 Cimetidine composition chewable tablets and preparation method thereof
US11103581B2 (en) 2015-08-31 2021-08-31 Acura Pharmaceuticals, Inc. Methods and compositions for self-regulated release of active pharmaceutical ingredient
WO2017151571A1 (en) * 2016-02-29 2017-09-08 First Time Us Generics Llc Abuse deterrent soft chewable drug formulations
AU2017262630A1 (en) 2016-05-12 2018-11-22 Bayer Animal Health Gmbh Method for the production of molded bodies for administration to animals
US10323226B2 (en) 2017-03-30 2019-06-18 Nch Corporation Feed material for biomass generator
EP3878436A1 (en) 2020-03-09 2021-09-15 Bayer Animal Health GmbH Soft chewable formed body for the administration to animals
WO2022015784A1 (en) 2020-07-15 2022-01-20 Schabar Research Associates Llc Unit oral dose compositions composed of ibuprofen and famotidine for the treatment of acute pain and the reduction of the severity and/or risk of heartburn
CA3124579A1 (en) 2020-07-15 2022-01-15 Schabar Research Associates Llc Unit oral dose compositions composed of naproxen sodium and famotidine for the treatment of acute pain and the reduction of the severity of heartburn and/or the risk of heartburn
US20240130974A1 (en) * 2022-10-19 2024-04-25 Genexa Inc. Solid pharmaceutical tablet

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3619292A (en) * 1968-07-15 1971-11-09 Penick & Ford Ltd Tablets and method of forming
US4760094A (en) * 1986-10-21 1988-07-26 American Home Products Corporation (Del.) Spray dried acetaminophen
US4851226A (en) * 1987-11-16 1989-07-25 Mcneil Consumer Products Company Chewable medicament tablet containing means for taste masking
US5075114A (en) 1990-05-23 1991-12-24 Mcneil-Ppc, Inc. Taste masking and sustained release coatings for pharmaceuticals
US5275823A (en) * 1989-04-27 1994-01-04 Smith Kline & French Laboratories Ltd. Pharmaceutical compositions
US5460825A (en) * 1990-05-23 1995-10-24 Mcneil-Ppc, Inc. Taste mask coatings for preparing chewable pharmaceutical tablets
US5464632A (en) 1991-07-22 1995-11-07 Laboratoires Prographarm Rapidly disintegratable multiparticular tablet
US5489436A (en) 1991-06-14 1996-02-06 Mcneil-Ppc, Inc. Taste mask coatings for preparation of chewable pharmaceutical tablets
US5609883A (en) 1994-09-16 1997-03-11 Advanced Technology Pharmaceuticals Corporation Compressed tablet transitory lubricant system
US5686107A (en) * 1995-01-30 1997-11-11 Fmc Corporation Chewable pharmaceutical tablets
WO1998046215A1 (en) 1997-04-16 1998-10-22 Cima Labs Inc. Rapidly dissolving robust dosage form
US5876759A (en) 1993-07-27 1999-03-02 Mcneil-Ppc, Inc. Rapidly disintegrating pharmaceutical dosage form and process for preparation thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3431339A (en) * 1966-07-20 1969-03-04 Colgate Palmolive Co Dentifrices
GB8426152D0 (en) * 1984-10-16 1984-11-21 Reckitt & Colmann Prod Ltd Medicinal compositions
CA1259924A (en) * 1985-03-25 1989-09-26 Wallace E. Becker Pharmaceutical tableting method
US5536526A (en) * 1988-01-11 1996-07-16 Cultor Ltd. Xylitol-based binding and diluting agent and a process for the production thereof
US4866046A (en) * 1988-05-31 1989-09-12 Top Laboratories, Inc. Low-dosage sublingual aspirin
DK71993D0 (en) * 1993-06-18 1993-06-18 Novo Nordisk As ENZYME
US5529783A (en) * 1994-12-19 1996-06-25 Mcneil-Ppc, Inc. Rotor granulation and coating of acetaminophen, pseudoephedrine, chlorpheniramine, and, optionally dextromethorphan
NZ332832A (en) * 1996-06-17 1999-07-29 Janssen Pharmaceutica Nv A process for preparing biconvex rapidly disintegrating dosage forms
US6270790B1 (en) * 1998-08-18 2001-08-07 Mxneil-Ppc, Inc. Soft, convex shaped chewable tablets having reduced friability

Patent Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3619292A (en) * 1968-07-15 1971-11-09 Penick & Ford Ltd Tablets and method of forming
US4760094A (en) * 1986-10-21 1988-07-26 American Home Products Corporation (Del.) Spray dried acetaminophen
US4851226A (en) * 1987-11-16 1989-07-25 Mcneil Consumer Products Company Chewable medicament tablet containing means for taste masking
US5275823A (en) * 1989-04-27 1994-01-04 Smith Kline & French Laboratories Ltd. Pharmaceutical compositions
US5075114A (en) 1990-05-23 1991-12-24 Mcneil-Ppc, Inc. Taste masking and sustained release coatings for pharmaceuticals
US5460825A (en) * 1990-05-23 1995-10-24 Mcneil-Ppc, Inc. Taste mask coatings for preparing chewable pharmaceutical tablets
US5489436A (en) 1991-06-14 1996-02-06 Mcneil-Ppc, Inc. Taste mask coatings for preparation of chewable pharmaceutical tablets
US5464632A (en) 1991-07-22 1995-11-07 Laboratoires Prographarm Rapidly disintegratable multiparticular tablet
US5464632C1 (en) 1991-07-22 2001-02-20 Prographarm Lab Rapidly disintegratable multiparticular tablet
US5876759A (en) 1993-07-27 1999-03-02 Mcneil-Ppc, Inc. Rapidly disintegrating pharmaceutical dosage form and process for preparation thereof
US5609883A (en) 1994-09-16 1997-03-11 Advanced Technology Pharmaceuticals Corporation Compressed tablet transitory lubricant system
US5686107A (en) * 1995-01-30 1997-11-11 Fmc Corporation Chewable pharmaceutical tablets
WO1998046215A1 (en) 1997-04-16 1998-10-22 Cima Labs Inc. Rapidly dissolving robust dosage form

Non-Patent Citations (19)

* Cited by examiner, † Cited by third party
Title
Ambros et al., The Characterization of the Mechanical Strength of Chewable Tablets, Pharm. Develop. Technol. 3, No. 4 pp. 509-15, 1998.*
Aulton, M.E., Pharm. Helv. vol. 56, No. 12, p. 332-6 (1981).
Chakrabarti et al. The Indian Journal of Pharmacy, vol. 37, No. 3, p. 62-65 (1975).
Chowhan et al. Journal of Pharmaceutical Sciences, vol. 81, No. 3, p. 290-94 (1992).
Danckwerts et al., The Effect of Processing Variables in the Compression Properties of Controlled Release Core-In-Cup Compressed Tablets from a New Adjustable Punch, International Journal of Pharmaceutics, 123 pp. 85-94, 1995.*
Gold et al., Journal of Pharmaceutical Sciences, vol. 69, No. 4, p. 384-386 (1980).
Gold et al., Pharmaceutical Technology, Dec. 1983, p. 31-38 and 71 (1983).
Horikoshi, et al. Chem. Pharm. Bull., vol. 21, No. 10, p. 2136-40 (1973).
Hwang et al. Drug Development and Industrial Pharmacy, vol. 19, No. 5, p. 507-19 (1973).
J. Pharm. Pharmac., vol. 24, p. 503-504 (1992).
Kigasawa et al. Yakugaku Zasshi, vol. 95, No. 7, p. 769-773 (1975).
Leonard et al., Drug Development and Industrial Pharmacy, vol. 15, No. 3, p. 434-359 (1989).
Morris et al., Characterization and Performance of a New Direct Compression Excipient for Chewable Tablets: Xylitab, Drug Dev. Ind. Pharm., 22, No. 9-10 pp. 925-32, 1996.*
Muntean et al., Formulation and Preparation of Some Chewable Tablets for Local Treatment of Bucco-Pharyngeal Infections, Farmacia 41, No. 1-2, pp. 51-56, 1993.*
Muresan et al., Stability Study if Pyroxicam in the Presence of Auxiliary Substances of Compression, Farmacia 41, No. 1-2, pp. 51-56, 1993.*
Pitt et al., J. Pharm. Pharmacol., vol. 41, p. 289-292 (1989).
Pitt et al., J. Pharma. Pharmacol., vol. 42, p. 219-225 (1990).
Sugimori et al. Powder Technology, vol. 58, p. 259-264 (1989).
Westerhuis et al., Optimisation of the Composition and Production of Mannitoll/Microcrystalline Cellulose Tablets, International Journal of Pharmaceutics, 143 pp. 151-162, 1996.*

Cited By (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030049316A1 (en) * 1998-08-18 2003-03-13 Robinson Ronni L. Soft chewable tablets
US7029699B2 (en) 1998-08-18 2006-04-18 Robinson Ronni L Soft chewable tablets
US20020122823A1 (en) * 2000-12-29 2002-09-05 Bunick Frank J. Soft tablet containing dextrose monohydrate
US20110142931A1 (en) * 2000-12-29 2011-06-16 Bunick Frank J Soft tablet containing dextrose monohydrate
US20030096791A1 (en) * 2001-05-31 2003-05-22 Cima Labs Inc. Taste masking of highly water-soluble drugs
US7226614B2 (en) 2001-06-28 2007-06-05 Ucb Farchim Sa Tablet comprising cetirizine and pseudoephedrine
US20060034928A1 (en) * 2001-06-28 2006-02-16 Domenico Fanara Tablet comprising cetirizine and pseudoephedrine
US20040170690A1 (en) * 2001-06-28 2004-09-02 Domenico Fanara Tablet comprising cetirizine and pseudoephedrine
US7014867B2 (en) 2001-06-28 2006-03-21 Ucb Farchim Sa Tablet comprising cetirizine and pseudoephedrine
US6790980B1 (en) 2001-08-31 2004-09-14 First Horizon Pharmaceutical Corporation Tannate compositions and methods of treatment
US8673190B2 (en) 2001-09-28 2014-03-18 Mcneil-Ppc, Inc. Method for manufacturing dosage forms
US8114328B2 (en) 2001-09-28 2012-02-14 Mcneil-Ppc, Inc. Method of coating a dosage form comprising a first medicant
US7635490B2 (en) 2001-09-28 2009-12-22 Mcneil-Ppc, Inc. Modified release dosage form
US20030068373A1 (en) * 2001-09-28 2003-04-10 Joseph Luber Immediate release tablet
US7323192B2 (en) * 2001-09-28 2008-01-29 Mcneil-Ppc, Inc. Immediate release tablet
US7838026B2 (en) 2001-09-28 2010-11-23 Mcneil-Ppc, Inc. Burst-release polymer composition and dosage forms comprising the same
US20030109565A1 (en) * 2001-12-10 2003-06-12 Daniel Wils Antipyretic preparation containing xylitol
US20030215502A1 (en) * 2002-03-20 2003-11-20 Elan Pharma International Limited Fast dissolving dosage forms having reduced friability
WO2003080023A3 (en) * 2002-03-20 2004-04-08 Elan Pharma Int Ltd Fast dissolving dosage forms having reduced friability
US7482022B2 (en) 2002-04-04 2009-01-27 Pfizer Inc. Palatable chewable tablet
EP2314171A1 (en) 2002-08-13 2011-04-27 Intervet International BV Compositions and process for delivering an additive
US8173161B2 (en) * 2002-12-04 2012-05-08 Mcneil-Ppc, Inc. Method of administering a pharmaceutical active ingredient
US20090258039A1 (en) * 2002-12-04 2009-10-15 Bunick Frank J Method of administering a pharmaceutical active ingredient
US7282217B1 (en) * 2003-08-29 2007-10-16 Kv Pharmaceutical Company Rapidly disintegrable tablets
US20050226908A1 (en) * 2004-04-07 2005-10-13 Akzo Nobel N.V. Efficacious composition of a benzimidazole, an avermectin and praziquantel and related methods of use
WO2005099692A1 (en) * 2004-04-07 2005-10-27 Intervet International B.V Efficacious composition of a benzimidazole, an avermectin and praziquantel and related methods of use
US8758816B2 (en) 2004-11-24 2014-06-24 Meda Pharmaceuticals Inc. Compositions comprising azelastine and methods of use thereof
US9919050B2 (en) 2004-11-24 2018-03-20 Meda Pharmaceuticals Inc. Compositions comprising azelastine
EP2522365A1 (en) 2004-11-24 2012-11-14 Meda Pharmaceuticals Inc. Compositions comprising azelastine and methods of use thereof
US8518919B2 (en) 2004-11-24 2013-08-27 Meda Pharmaceuticals Inc. Compositions comprising azelastine and methods of use thereof
EP2377557A2 (en) 2004-11-24 2011-10-19 MedPointe Healthcare Inc. Compositions comprising azelastine and methods of use thereof
US8071073B2 (en) 2004-11-24 2011-12-06 Meda Pharmaceuticals Inc. Compositions comprising azelastine and methods of use thereof
WO2006058022A1 (en) 2004-11-24 2006-06-01 Medpointe Healthcare Inc. Compositions comprising azelastine and methods of use thereof
US10064817B2 (en) 2004-11-24 2018-09-04 Meda Pharmaceuticals Inc. Compositions comprising azelastine and methods of use thereof
EP2486942A1 (en) 2004-11-24 2012-08-15 Meda Pharmaceuticals Inc. Compositions comprising azelastine and methods of use thereof
US20080161417A1 (en) * 2005-05-08 2008-07-03 Li Zhao Xylitol Granules Capable of Directly Being Compressible Into Tablets and Preparation Process Thereof
US8007825B2 (en) 2005-09-30 2011-08-30 Mcneil-Ppc, Inc. Oral compositions containing a salivation inducing agent
US20090191267A1 (en) * 2005-09-30 2009-07-30 Wynn David W Oral Compositions Containing a Salivation Inducing Agent
US20080181932A1 (en) * 2007-01-30 2008-07-31 Drugtech Corporation Compositions for oral delivery of pharmaceuticals
US10548847B2 (en) 2007-08-03 2020-02-04 Choongwae Pharma Corporation Composition for manufacturing orally disintegrating dosage form to protect coating layer of active substance
WO2009020268A1 (en) 2007-08-03 2009-02-12 Choongwae Pharma Corporation Composition for manufacturing orally disintegrating dosage form to protect coating layer of active substance
US20100190739A1 (en) * 2008-12-15 2010-07-29 Fleming And Company, Pharmaceuticals Rapidly Dissolving Vitamin Formulation and Methods of Using the Same
WO2013068371A1 (en) 2011-11-08 2013-05-16 Intervet International B.V. Soft chewable dosage form compositions of cannabinoid receptor type 1 (cb-1) antagonists
US9259417B2 (en) 2012-02-06 2016-02-16 Merial, Inc. Parasiticidal oral veterinary compositions comprising systemically-acting active agents, methods and uses thereof
EP3766491A1 (en) 2012-02-06 2021-01-20 Boehringer Ingelheim Animal Health USA Inc. Parasiticidal oral veterinary compositions comprising systemically-acting active agents, methods and uses thereof
EP3061454A1 (en) 2012-02-06 2016-08-31 Merial, Inc. Parasiticidal oral veterinary compositions comprising systemically-acting active agents, methods and uses thereof
US10596156B2 (en) 2012-02-06 2020-03-24 Boehringer Ingelheim Animal Health USA Inc. Parasiticidal oral veterinary compositions comprising systemically-acting active agents, methods and uses thereof
WO2013119442A1 (en) 2012-02-06 2013-08-15 Merial Limited Parasiticidal oral veterinary compositions comprising systemically-acting active agents, methods and uses thereof
US9931320B2 (en) 2012-02-06 2018-04-03 Merial Inc. Parasiticidal oral veterinary compositions comprising systemically-acting active agents, methods and uses thereof
US9233100B2 (en) 2012-02-06 2016-01-12 Merial, Inc. Parasiticidal oral veterinary compositions comprising systemically-acting active agents, methods and uses thereof
US12396945B2 (en) 2012-04-04 2025-08-26 Intervet Inc. Soft chewable pharmaceutical products
US11285101B2 (en) 2012-04-04 2022-03-29 Intervet Inc. Soft chewable pharmaceutical products
US11337917B2 (en) 2012-04-04 2022-05-24 Intervet Inc. Soft chewable pharmaceutical products
WO2016033424A1 (en) 2014-08-29 2016-03-03 Genzyme Corporation Methods for the prevention and treatment of major adverse cardiovascular events using compounds that modulate apolipoprotein b
WO2016134846A1 (en) 2015-02-27 2016-09-01 Rottapharm Ltd. Composition for the treatment of acne
WO2017008909A1 (en) 2015-07-16 2017-01-19 Rottapharm S. P. A. Oral formulation comprising berberine and morus alba extract
US11633361B2 (en) 2015-12-19 2023-04-25 First Time Us Generics Llc Soft chew pharmaceutical formulations
US10117831B2 (en) 2015-12-19 2018-11-06 First Time Us Generics Llc Soft chew pharmaceutical formulations
JPWO2019004155A1 (en) * 2017-06-27 2020-04-23 第一三共株式会社 tablet
JP7203726B2 (en) 2017-06-27 2023-01-13 第一三共株式会社 tablet
US11033502B2 (en) * 2017-06-27 2021-06-15 Daiichi Sankyo Company, Limited Tablet
WO2022133420A1 (en) 2020-12-18 2022-06-23 Boehringer Ingelheim Animal Health USA Inc. Boron containing pyrazole compounds, compositions comprising them, methods and uses thereof
IT202100016310A1 (en) * 2021-06-22 2022-12-22 Alaia Idea S R L Method for making tablets
US20230123099A1 (en) * 2021-10-15 2023-04-20 Fertin Pharma A/S Dextrose tablets with improved mouthfeel

Also Published As

Publication number Publication date
DE69937780T2 (en) 2008-12-04
DE69937780D1 (en) 2008-01-31
AU773549B2 (en) 2004-05-27
NZ337310A (en) 2000-05-26
SA99200655B1 (en) 2006-08-22
EP0997143A3 (en) 2001-11-14
CA2280628A1 (en) 2000-02-18
AU4456599A (en) 2000-03-09
ES2299234T3 (en) 2008-05-16
JP2000095673A (en) 2000-04-04
CN1249176A (en) 2000-04-05
US7029699B2 (en) 2006-04-18
ATE381320T1 (en) 2008-01-15
BR9903736A (en) 2000-09-26
CA2280628C (en) 2009-02-10
US20010043947A1 (en) 2001-11-22
AR022065A1 (en) 2002-09-04
KR20000017352A (en) 2000-03-25
ZA995248B (en) 2001-02-19
CO5130019A1 (en) 2002-02-27
US20030049316A1 (en) 2003-03-13
EP0997143A2 (en) 2000-05-03
US6471991B2 (en) 2002-10-29
EP0997143B1 (en) 2007-12-19
PT997143E (en) 2008-02-07

Similar Documents

Publication Publication Date Title
US6270790B1 (en) Soft, convex shaped chewable tablets having reduced friability
US5876759A (en) Rapidly disintegrating pharmaceutical dosage form and process for preparation thereof
US7223421B2 (en) Teste masked pharmaceutical particles
US6277409B1 (en) Protective coating for tablet
JP3157190B2 (en) Taste masking and long acting coatings for drugs
EP1058538B9 (en) Fast disintegrating tablets
AU783593B2 (en) Texture masked particles containing an active ingredient
CN100379407C (en) Process for producing chewable dispersible tablets
US8496969B2 (en) Soft tablet containing high molecular weight cellulosics
US20110142931A1 (en) Soft tablet containing dextrose monohydrate
AU620866B2 (en) Pharmaceutical compositions
US20090104267A1 (en) Soft tablet containing high molecular weight cellulosics
MXPA99007660A (en) Chewable tablets sua

Legal Events

Date Code Title Description
AS Assignment

Owner name: MCNEIL-PPC, INC., NEW JERSEY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ROBINSON, RONNI;DAMON, JAMES R.;MOSSOP, JAMES R.;AND OTHERS;REEL/FRAME:009812/0958

Effective date: 19990217

STCF Information on status: patent grant

Free format text: PATENTED CASE

FPAY Fee payment

Year of fee payment: 4

FPAY Fee payment

Year of fee payment: 8

FPAY Fee payment

Year of fee payment: 12

AS Assignment

Owner name: JOHNSON & JOHNSON CONSUMER INC., NEW JERSEY

Free format text: MERGER AND CHANGE OF NAME;ASSIGNORS:MCNEIL-PPC, INC.;JOHNSON & JOHNSON CONSUMER INC.;REEL/FRAME:036049/0254

Effective date: 20150623